Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

SI-BONE, Inc. Common Stock

SIBN

SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Last trade $23.13
Day change -$0.285 (-1.22%)
Day range $22.96 – $23.48
Volume 347,523
Market cap $1.06B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.06B
Price / earnings
—
Price / book
5.72×
Price / sales
4.79×
EV / sales
4.79×
EV / EBITDA
-104.75×

Profitability

Earnings per share
-$0.30
Return on assets
-5.33%
Return on equity
-7.41%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.19×
Current ratio
7.58×
Quick ratio
6.15×
Cash ratio
1.19×

Cash flow

Price / cash flow
173.61×
Price / free cash flow
—
Free cash flow
-$4.19M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SIBN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$55.7M$56.01M$52.59M$56.35M$48.66M$48.63M$47.29M$49M
Cost of revenue$11.54M$11.46M$10.64M$11.82M$9.81M$9.82M$9.6M$10.23M
Gross profit$44.17M$44.55M$41.94M$44.53M$38.85M$38.81M$37.7M$38.78M
Selling, general and administrative$43.96M$44.13M$42.85M$42.63M$39.99M$41.5M$40.64M$40.4M
Research and development$4.56M$5.22M$4.19M$4.36M$4.24M$4.31M$4.53M$3.87M
Total operating expenses$48.52M$49.35M$47.04M$46.99M$44.23M$45.81M$45.18M$44.27M
Operating income-$4.35M-$4.81M-$5.09M-$2.46M-$5.38M-$7M-$7.48M-$5.49M
Interest expense-$608K-$598K-$592K-$630K-$670K-$666K-$662K-$793K
Income before taxes-$3.62M-$4.09M-$4.33M-$1.64M-$4.57M-$6.15M-$6.54M-$4.5M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.62M-$4.09M-$4.33M-$1.64M-$4.57M-$6.15M-$6.54M-$4.5M
Net income attributable to common shareholders-$3.62M-$4.09M-$4.33M-$1.64M-$4.57M-$6.15M-$6.54M-$4.5M
EBITDA-$2.66M-$3.13M-$3.48M-$825K-$3.9M-$5.64M-$6.2M-$4.28M
Basic earnings per share-$0.08-$0.09-$0.10-$0.04-$0.11-$0.14-$0.15-$0.11
Diluted earnings per share-$0.08-$0.09-$0.10-$0.04-$0.11-$0.14-$0.15-$0.11

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates

Si-Bone (SIBN) reported a quarterly loss of $0.08 per share, beating the consensus estimate of $0.13 loss by 38.46%, with revenues of $55.7 million slightly exceeding expectations. The company has surpassed consensus estimates four times over the last four quarters. However, shares have underperformed the S&P 500 year-to-date, gaining 7.7% versus the market's 10.7%. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

The Motley Fool

Why Si-Bone Stock Soared by Almost 20% on Tuesday

Si-Bone (SIBN) stock surged nearly 20% on Tuesday following strong first-quarter 2026 results. The medical device company reported $52.6 million in revenue (up 11% YoY) and significantly narrowed its net loss to $4.3 million. The company also received FDA clearance for its iFuse INTRA Ti implant system and raised full-year guidance to $230-233 million, up from the previous $228.5-232.5 million forecast.

GlobeNewswire Inc.

Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026

Smith+Nephew announced it will showcase advanced orthopaedic technologies at AAOS 2026, including its CORI handheld robotic surgical system for hip, knee and shoulder arthroplasty, new trauma solutions like the EVOS plating system, and an expanded ASC portfolio. The company also announced distribution agreements with SI-BONE for pelvic fracture solutions and RMR Ortho for nitinol fixation technology.

GlobeNewswire Inc.

Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026

Smith+Nephew will showcase its rotator cuff repair portfolio at AAOS 2026, featuring the newly acquired Tendon Seam Repair System and REGENETEN Bioinductive Implant. The company also announced exclusive US distribution agreements with RMR Ortho for A'TOMIC nitinol fixation technology and SI-BONE for their iFuse TORQ portfolio, expanding its orthopedic offerings.

GlobeNewswire Inc.

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

SI-BONE announced preliminary Q4 2025 revenue of $56.2-$56.3 million (~15% growth) and full year 2025 revenue of $200.8-$200.9 million (~20% growth). The company reported ~1,640 active U.S. physicians (18% increase) and cash equivalents of ~$147.7 million with net cash generation of ~$2.0 million in Q4. Final audited results will be provided in late February 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.